Surgical endoscopy · 2025
Concurrent hiatal hernia repair and gastric bypass as an adjunct in the treatment of hiatal hernia in populations with obesity.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Siegel Leon, Carroll Rory, Thompson Dakota T, Lehmann Ryan, Smith Jessica, Nau Peter
Аннотация
BACKGROUND: Minimally invasive hiatal hernia repair with fundoplication (HHR) is the standard of care for hiatal hernias but has a high risk of recurrence even in populations without obesity. Concomitant roux-en-y gastric bypass (RYGB) with HHR may mitigate the increased risk of hiatal hernia recurrence in patients with obesity while also addressing obesity-related comorbidities. There is a paucity of data on this procedure. It is hypothesized that a concomitant RYGB with HHR is safe and effective in patients with obesity.
METHODS: This is a single institution retrospective review of adult patients who underwent concomitant RYGB with HHR from 2014-2023. Patient charts were reviewed to collect data on complications, weight loss, GERD symptom resolution, and improvement in other obesity-related comorbidities. Outcomes were measured at one-, three-, and five-year follow-up.
RESULTS: Sixty-four patients met inclusion criteria. Fifty-three patients had primary and eleven patients had revisional surgery. There was one (2%) perioperative complication that required intervention, three (4%) unplanned readmissions for PO intolerance, and four patients (8%) treated for marginal ulcer. Resolution of heartburn/reflux symptoms was 86% at one year, 70% at 3 year, and 59% at 5 year follow-up. Improvement in diabetes (80%), hypertension (75%), and hyperlipidemia (33%) were noted at 5 years. The change in BMI and %TWL at 5 years for primary procedures was -11.5 kg/m2 and 37.7%, respectively. For revisional procedures, change in BMI was -2.4 kg/m2 and %TWL was 3.6%.
CONCLUSION: Durability of a HHR in the setting of obesity is poor. Concomitant RYGB with HHR is safe and effective for treating GERD while also improving obesity and obesity-associated comorbidities.
METHODS: This is a single institution retrospective review of adult patients who underwent concomitant RYGB with HHR from 2014-2023. Patient charts were reviewed to collect data on complications, weight loss, GERD symptom resolution, and improvement in other obesity-related comorbidities. Outcomes were measured at one-, three-, and five-year follow-up.
RESULTS: Sixty-four patients met inclusion criteria. Fifty-three patients had primary and eleven patients had revisional surgery. There was one (2%) perioperative complication that required intervention, three (4%) unplanned readmissions for PO intolerance, and four patients (8%) treated for marginal ulcer. Resolution of heartburn/reflux symptoms was 86% at one year, 70% at 3 year, and 59% at 5 year follow-up. Improvement in diabetes (80%), hypertension (75%), and hyperlipidemia (33%) were noted at 5 years. The change in BMI and %TWL at 5 years for primary procedures was -11.5 kg/m2 and 37.7%, respectively. For revisional procedures, change in BMI was -2.4 kg/m2 and %TWL was 3.6%.
CONCLUSION: Durability of a HHR in the setting of obesity is poor. Concomitant RYGB with HHR is safe and effective for treating GERD while also improving obesity and obesity-associated comorbidities.